Fusen Pharmaceutical Company Limited provided group earnings guidance for the six months ended 30 June 2023. The group expects to record profit attributable to Shareholders with a range from approximately RMB 10 million to RMB 25 million for the six months ended 30 June 2023, as compared with the loss attributable to Shareholders of approximately RMB 7.0 million for the six months ended 30 June 2022.